Clinical characteristics and outcomes of young and very young adults with heart failure: The CHARM programme (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity).

[1]  C. Bhamidipati,et al.  Orthotopic heart transplant versus left ventricular assist device: a national comparison of cost and survival. , 2013, The Journal of thoracic and cardiovascular surgery.

[2]  Mike Rayner,et al.  Coronary Heart Disease Statistics 2012 , 2012 .

[3]  Nicola J Cooper,et al.  Cost-effectiveness of the implantable HeartMate II left ventricular assist device for patients awaiting heart transplantation. , 2012, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[4]  D. Mozaffarian,et al.  Heart disease and stroke statistics--2012 update: a report from the American Heart Association. , 2012, Circulation.

[5]  L. Køber,et al.  Clinical characteristics and major comorbidities in heart failure patients more than 85 years of age compared with younger age groups , 2011, European journal of heart failure.

[6]  A. Rigby,et al.  The national heart failure audit for England and Wales 2008–2009 , 2010, Heart.

[7]  J. Gardin,et al.  Racial differences in incident heart failure among young adults. , 2009, The New England journal of medicine.

[8]  C. Yancy,et al.  Characteristics and in-hospital outcomes for nonadherent patients with heart failure: findings from Get With The Guidelines-Heart Failure (GWTG-HF). , 2009, American heart journal.

[9]  L. Tavazzi,et al.  Clinical characteristics, management, and prognosis of octogenarians with acute heart failure admitted to cardiology wards: results from the Italian Survey on Acute Heart Failure. , 2009, American heart journal.

[10]  C. Yancy,et al.  Influence of age on the management of heart failure: findings from Get With the Guidelines-Heart Failure (GWTG-HF). , 2009, American heart journal.

[11]  G. Fonarow,et al.  Influence of patient age and sex on delivery of guideline-recommended heart failure care in the outpatient cardiology practice setting: findings from IMPROVE HF. , 2009, American heart journal.

[12]  C. O'connor,et al.  Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). , 2008, American heart journal.

[13]  S. Allender,et al.  Coronary heart disease statistics. , 2008 .

[14]  A. Gavazzi,et al.  Baseline characteristics of patients recruited in the AREA IN-CHF study (Antiremodelling Effect of Aldosterone Receptors Blockade with Canrenone in Mild Chronic Heart Failure) , 2007, Journal of cardiovascular medicine.

[15]  F. Formiga,et al.  Hospitalization due to acute heart failure. Role of the precipitating factors. , 2007, International journal of cardiology.

[16]  B. Massie,et al.  Heart failure in community practice: relationship to age and sex in a beta-blocker registry. , 2006, Congestive heart failure.

[17]  Salim Yusuf,et al.  Predictors of mortality and morbidity in patients with chronic heart failure. , 2006, European heart journal.

[18]  M. Pfeffer,et al.  Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial , 2005, The Lancet.

[19]  J. Daubert,et al.  Baseline characteristics of patients recruited into the CARE‐HF study , 2005, European journal of heart failure.

[20]  D. J. Veldhuisen,et al.  Influence of age on natriuretic peptides in patients with chronic heart failure: a comparison between ANP/NT‐ANP and BNP/NT‐proBNP , 2005, European journal of heart failure.

[21]  L. Melton,et al.  Epidemiology of Idiopathic Dilated and Hypertrophic Cardiomyopathy , 2005 .

[22]  H. Krumholz,et al.  Age, functional capacity, and health-related quality of life in patients with heart failure. , 2004, Journal of cardiac failure.

[23]  S. Gottlieb,et al.  Efficacy, safety and tolerability of β-adrenergic blockade with metoprolol CR/XL in elderly patients with heart failure , 2004 .

[24]  Brian Baker,et al.  The influence of age, gender, and race on the prevalence of depression in heart failure patients. , 2004, Journal of the American College of Cardiology.

[25]  S. Gottlieb,et al.  Efficacy, safety and tolerability of beta-adrenergic blockade with metoprolol CR/XL in elderly patients with heart failure. , 2004, European heart journal.

[26]  Karl Swedberg,et al.  Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial , 2003, The Lancet.

[27]  Karl Swedberg,et al.  Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial , 2003, The Lancet.

[28]  M. Pfeffer,et al.  Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial , 2003, The Lancet.

[29]  M. Pfeffer,et al.  Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme , 2003, The Lancet.

[30]  G. Fonarow,et al.  Compliance Behaviors of Elderly Patients With Advanced Heart Failure , 2003, The Journal of cardiovascular nursing.

[31]  M. Pfeffer,et al.  Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure—Assessment of Reduction in Mortality and morbidity (CHARM) programme , 2003, European journal of heart failure.

[32]  N. Freemantle,et al.  The EuroHeart Failure Survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment , 2003 .

[33]  N Freemantle,et al.  The EuroHeart Failure survey programme-- a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. , 2003, European heart journal.

[34]  N. Freemantle,et al.  Relation of sex, age and concomitant diseases to drug prescription for heart failure in primary care in Europe. , 2003, European journal of heart failure.

[35]  A. Matsumori,et al.  Epidemiology of idiopathic cardiomyopathy in Japan: results from a nationwide survey , 2002, Heart.

[36]  M. Pfeffer,et al.  Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators. , 1999, Journal of cardiac failure.

[37]  P. Poole‐Wilson,et al.  Baseline clinical characteristics of patients recruited into the assessment of treatment with lisinopril and survival study , 1999, European journal of heart failure.

[38]  E. J. Brown,et al.  The effect of digoxin on mortality and morbidity in patients with heart failure. , 1997, The New England journal of medicine.

[39]  L. Melton,et al.  Epidemiology of idiopathic dilated and hypertrophic cardiomyopathy. A population-based study in Olmsted County, Minnesota, 1975-1984. , 1989, Circulation.

[40]  Daan Brandenbarg.  The National. , 1892 .